Friday - March 29, 2024
European Medicines Agency Grants PRIME, Advanced Therapy Medicinal Product Designations to Janssen RPGR Gene Therapy for X-Linked Retinitis Pigmentosa
March 03, 2020
RARITAN, New Jersey, March 3 -- Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, issued the following news release:

* * *

- Only RPGR gene therapy program to receive PRIME designation

- Designations will accelerate the regulatory review timeline of this potential gene therapy for European patients living with X-linked retinitis pigmentosa

* * *

The Janssen Pharmaceutical Companies of Johnson & Johnson an . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products